Suppr超能文献

广泛的临床经验:促肾上腺皮质激素非依赖性皮质醇增多症患者肾上腺切除术后下丘脑-垂体-肾上腺轴的恢复。

Extensive clinical experience: Hypothalamic-pituitary-adrenal axis recovery after adrenalectomy for corticotropin-independent cortisol excess.

机构信息

Division of Endocrinology, Diabetes, Metabolism & Nutrition, Mayo Clinic, Rochester, Minnesota.

出版信息

Clin Endocrinol (Oxf). 2018 Dec;89(6):721-733. doi: 10.1111/cen.13803. Epub 2018 Jul 23.

Abstract

OBJECTIVE

To identify predictors of hypothalamic-pituitary-adrenal (HPA) axis recovery interval and severity of glucocorticoid withdrawal symptoms (GWS) in patients undergoing adrenalectomy for corticotropin-independent cortisol excess.

DESIGN

This is a retrospective study of patients with mild autonomous cortisol excess (MACE), moderate and severe Cushing syndrome (CS) who developed adrenal insufficiency after unilateral adrenalectomy between 1998 and 2017.

RESULTS

Adrenalectomy was performed in 81 patients (79% women, median age 52 years [IQR 42-62]). HPA axis recovery occurred at a median of 4.3 months (IQR 1.6-11.4) after adrenalectomy (severe CS vs moderate CS vs MACE: median 11.4 vs 2.8 vs 2.1 months, P < 0.01). Main predictors of HPA axis recovery interval included: preoperative serum cortisol concentration after 1-mg overnight dexamethasone suppression test >10 μg/dL or >276 nmol/L (9.7 vs 1.3 months if cortisol ≤10 μg/dL or ≤276 nmol/L, P < 0.01); body mass index (for every 3 kg/m decrease, glucocorticoid taper increased by 1 month, P < 0.05); age <45 (11.4 vs 2.3 months if ≥45 years, P < 0.05); duration of symptoms prior to diagnosis >1 year (11.4 vs 2.8 months if ≤1 year); moon facies (11.4 vs 2.2 months if no rounding of the face); and myopathy (13.1 vs 2.7 months if no myopathy, P < 0.05). Patients with severe CS had a higher incidence of GWS compared to patients with MACE (66.7% vs 40.0%, P < 0.05) with a median of 1 and 0 events/patient, respectively.

CONCLUSIONS

The HPA axis recovery interval was the longest for patients with severe CS. Surprisingly, patients with moderate CS recovered their HPA axis as quickly as those with MACE. Glucocorticoid withdrawal symptoms were observed in all groups, with more events in patients with severe CS. This study emphasizes the need to counsel patients on expectations for HPA axis recovery and address intervention for GWS based on individual preoperative parameters.

摘要

目的

确定接受肾上腺切除术治疗促肾上腺皮质激素非依赖性皮质醇过多的患者的下丘脑-垂体-肾上腺(HPA)轴恢复时间和糖皮质激素戒断症状(GWS)严重程度的预测因素。

设计

这是一项对 1998 年至 2017 年间单侧肾上腺切除术后发生肾上腺功能不全的轻度自主皮质醇过多(MACE)、中度和重度库欣综合征(CS)患者的回顾性研究。

结果

81 例患者接受了肾上腺切除术(79%为女性,中位年龄 52 岁[四分位距 42-62])。HPA 轴恢复发生在肾上腺切除术后中位数 4.3 个月(四分位距 1.6-11.4)(严重 CS 比中度 CS 比 MACE:中位数 11.4 比 2.8 比 2.1 个月,P<0.01)。HPA 轴恢复间隔的主要预测因素包括:1 毫克过夜地塞米松抑制试验后术前血清皮质醇浓度>10μg/dL 或>276nmol/L(如果皮质醇≤10μg/dL 或≤276nmol/L,则皮质醇为 9.7 比 1.3 个月,P<0.01);体重指数(每减少 3kg/m,皮质类固醇减量增加 1 个月,P<0.05);年龄<45 岁(如果≥45 岁,为 11.4 比 2.3 个月,P<0.05);诊断前症状持续时间>1 年(如果≤1 年,为 11.4 比 2.8 个月);满月脸(如果没有面部变圆,为 11.4 比 2.2 个月);肌病(如果没有肌病,为 13.1 比 2.7 个月,P<0.05)。与 MACE 患者相比,严重 CS 患者的 GWS 发生率更高(66.7%比 40.0%,P<0.05),分别为中位数 1 次和 0 次事件/患者。

结论

严重 CS 患者的 HPA 轴恢复间隔时间最长。令人惊讶的是,中度 CS 患者恢复 HPA 轴的速度与 MACE 患者一样快。所有组均观察到糖皮质激素戒断症状,但严重 CS 患者的事件更多。这项研究强调了需要告知患者对 HPA 轴恢复的期望,并根据个体术前参数解决 GWS 的干预问题。

相似文献

2
Predicting postoperative hypocortisolism in patients with non-aldosterone-producing adrenocortical adenoma: a retrospective single-centre study.
J Endocrinol Invest. 2024 Jul;47(7):1751-1762. doi: 10.1007/s40618-023-02283-1. Epub 2024 Feb 22.
4
Predictability of hypoadrenalism occurrence and duration after adrenalectomy for ACTH-independent hypercortisolism.
J Endocrinol Invest. 2018 Apr;41(4):485-493. doi: 10.1007/s40618-017-0788-6. Epub 2017 Nov 18.
6
Hypothalamic-pituitary-adrenal axis recovery after treatment of Cushing's syndrome.
J Neuroendocrinol. 2022 Aug;34(8):e13172. doi: 10.1111/jne.13172. Epub 2022 Jun 20.
7
The Short Synacthen (Corticotropin) Test Can Be Used to Predict Recovery of Hypothalamo-Pituitary-Adrenal Axis Function.
J Clin Endocrinol Metab. 2018 Aug 1;103(8):3050-3059. doi: 10.1210/jc.2018-00529.
8
Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome.
Pituitary. 2022 Jun;25(3):393-403. doi: 10.1007/s11102-022-01218-y. Epub 2022 Apr 26.
9
A Retrospective Study on Weaning Glucocorticoids and Recovery of the Hypothalamic-Pituitary-Adrenal Axis.
J Clin Endocrinol Metab. 2024 Oct 15;109(11):e2031-e2037. doi: 10.1210/clinem/dgae059.
10
Long-term basal and dynamic evaluation of hypothalamic-pituitary-adrenal (HPA) axis in acromegalic patients.
Clin Endocrinol (Oxf). 2008 Oct;69(4):608-12. doi: 10.1111/j.1365-2265.2008.03270.x. Epub 2008 Apr 10.

引用本文的文献

3
High recovery rate of adrenal function after successful surgical treatment of Cushing's syndrome.
Endocr Connect. 2025 Apr 4;14(5). doi: 10.1530/EC-24-0612. Print 2025 May 1.
4
Predictor of Steroid Replacement Duration after Removal of Cortisol-producing Adenoma.
Intern Med. 2025 May 15;64(10):1476-1484. doi: 10.2169/internalmedicine.4339-24. Epub 2024 Oct 18.
5
Targeting glucocorticoid receptor signaling pathway for treatment of stress-related brain disorders.
Pharmacol Rep. 2024 Dec;76(6):1333-1345. doi: 10.1007/s43440-024-00654-w. Epub 2024 Oct 3.
6
Glucocorticoid treatment and adrenal suppression in children: current view and open issues.
J Endocrinol Invest. 2025 Jan;48(1):37-52. doi: 10.1007/s40618-024-02461-9. Epub 2024 Oct 1.
9
Challenges in the postsurgical recovery of cushing syndrome: glucocorticoid withdrawal syndrome.
Front Endocrinol (Lausanne). 2024 Apr 12;15:1353543. doi: 10.3389/fendo.2024.1353543. eCollection 2024.
10
No requirement of perioperative glucocorticoid replacement in patients with endogenous Cushing's syndrome - a pilot study.
Endocrine. 2024 Aug;85(2):926-936. doi: 10.1007/s12020-024-03832-1. Epub 2024 Apr 22.

本文引用的文献

1
Adrenocortical Stress Response during the Course of Critical Illness.
Compr Physiol. 2017 Dec 12;8(1):283-298. doi: 10.1002/cphy.c170022.
2
Comparison of hydrocortisone and prednisone in the glucocorticoid replacement therapy post-adrenalectomy of Cushing's Syndrome.
Oncotarget. 2017 Aug 31;8(62):106113-106120. doi: 10.18632/oncotarget.20597. eCollection 2017 Dec 1.
3
Predictability of hypoadrenalism occurrence and duration after adrenalectomy for ACTH-independent hypercortisolism.
J Endocrinol Invest. 2018 Apr;41(4):485-493. doi: 10.1007/s40618-017-0788-6. Epub 2017 Nov 18.
4
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline.
J Clin Endocrinol Metab. 2016 Nov;101(11):3888-3921. doi: 10.1210/jc.2016-2118. Epub 2016 Oct 13.
7
Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study.
Lancet Diabetes Endocrinol. 2016 Jul;4(7):569-76. doi: 10.1016/S2213-8587(16)30005-5. Epub 2016 Jun 2.
8
Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline.
J Clin Endocrinol Metab. 2016 Feb;101(2):364-89. doi: 10.1210/jc.2015-1710. Epub 2016 Jan 13.
9
ACTH Stimulation Tests for the Diagnosis of Adrenal Insufficiency: Systematic Review and Meta-Analysis.
J Clin Endocrinol Metab. 2016 Feb;101(2):427-34. doi: 10.1210/jc.2015-1700. Epub 2015 Dec 9.
10
Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.
J Clin Endocrinol Metab. 2015 Aug;100(8):2807-31. doi: 10.1210/jc.2015-1818. Epub 2015 Jul 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验